Ysios Capital
Ysios Capital Partners, SGEIC, S.A.U. is a private equity and venture capital firm founded in 2008, based in Donostia-San Sebastián, Spain, with additional offices in Europe and North America. The firm specializes in seed and early-stage investments, focusing on human healthcare innovations, life sciences, biotechnology, and digital health sectors, particularly in pharmaceuticals, diagnostics, and medical devices. Ysios Capital aims to support the development of therapeutic and diagnostic products, investing between €1.22 million and €22.69 million in promising companies. The firm typically seeks to take a board seat in its portfolio companies and holds investments for four to six years, with exit strategies involving public offerings or mergers and acquisitions. With over €200 million in assets under management through its two funds, Ysios Capital emphasizes transforming scientific knowledge into successful businesses while targeting regions across North America and Europe.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.